5 big analyst AI moves: Nvidia, AMD upgraded; ASML seen on €1,000 path
Investing.com - RBC Capital has raised its price target on HealthEquity, Inc (NASDAQ:HQY) to $110.00 from $109.00 while maintaining an Outperform rating following the company’s strong quarterly performance. According to InvestingPro data, analysts’ targets range from $104 to $130, with the stock currently trading at $93.46.
The health savings account administrator delivered earnings that exceeded Wall Street expectations, with adjusted earnings per share beating estimates by approximately 18% and adjusted EBITDA surpassing projections by about 11%. The company’s strong financial performance is reflected in its impressive 65.52% gross margin and 19.21% revenue growth over the last twelve months.
RBC attributes the strong performance primarily to improvements in gross margin, noting that HealthEquity is taking steps to derisk its HSA cash portfolio with additional forward contracts in fiscal year 2026.
These measures are expected to set up yield improvement in fiscal year 2027 and beyond, while simultaneously reducing the company’s interest rate sensitivity.
RBC also highlighted HealthEquity’s use of artificial intelligence to strengthen service gross margins, while noting that questions remain about the company’s ability to drive improvement in sales growth and the cadence for improvement in HSA cash yield.
In other recent news, HealthEquity Inc. reported impressive financial results for the fiscal second quarter of 2025. The company delivered an earnings per share (EPS) of $1.08, surpassing analysts’ expectations of $0.92, resulting in a 17.39% surprise. Additionally, HealthEquity’s revenue reached $326 million, exceeding the anticipated $320.74 million. These figures highlight the company’s strong financial performance during this period. Despite these positive results, the company’s stock saw a slight decline in after-hours trading. The financial community is taking note of HealthEquity’s ability to outperform projections. Investors and analysts will be closely monitoring how the company continues to perform in the upcoming quarters. These developments underscore the importance of keeping an eye on HealthEquity’s financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.